{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:24:37Z","timestamp":1787066677443,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Programme Hospitalier de Recherche Clinique","award":["2003 and 2006"],"award-info":[{"award-number":["2003 and 2006"]}]},{"name":"Ligue Nationale de Recherche Contre le Cancer"},{"name":"Institut National sur le Cancer"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.beha.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T22:49:08Z","timestamp":1477003748000},"page":"271-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beyond tyrosine kinase inhibitors: Combinations and other agents"],"prefix":"10.1016","volume":"29","author":[{"given":"Emilie","family":"Cayssials","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.beha.2016.10.017_bib1","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"10.1016\/j.beha.2016.10.017_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2016.10.017_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.017_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2016.10.017_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.beha.2016.10.017_bib6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.017_bib7","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.10.017_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2008.1.436","article-title":"Chronic myeloid leukemia stem cells","author":"Jamieson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2016.10.017_bib9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","article-title":"Molecular pathways to CML stem cells","volume":"91","author":"Rice","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.beha.2016.10.017_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.017_bib11","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V95.2.404","article-title":"Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation","volume":"95","author":"Chomel","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI117473","article-title":"Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies","volume":"94","author":"Talpaz","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2016.10.017_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/sj.leu.2404893","article-title":"CD34+\/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate","volume":"22","author":"Bocchia","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.017_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/leu.2009.190","article-title":"Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy","volume":"24","author":"Mustjoki","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2016.10.017_bib16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.beha.2016.10.017_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.beha.2016.10.017_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.017_bib19","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.95.17.10152","article-title":"T\u00a0cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukaemia after allogeneic stem cell transplantation","volume":"95","author":"Smit","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.10.017_bib20","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib21","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2016.10.017_bib23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2011.143","article-title":"The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis","volume":"25","author":"Mar","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2016.10.017_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2016.10.017_bib25","series-title":"Poster Abstract 1428: 51st ASH Annual Meeting; Dec 5-8, New Orleans, LA","article-title":"Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells","author":"Irvine","year":"2009"},{"key":"10.1016\/j.beha.2016.10.017_bib26","series-title":"A\u00a0single-arm dose-finding phase IB multicenter study of the oral smoothened antagonist LDE225 in combination with nilotinib in chronic phase chronic myeloid leukemia patients who have failed prior therapy with other BCR-ABL tyrosine-kinase inhibitors","author":"Novartis Pharmaceuticals","year":"2012"},{"key":"10.1016\/j.beha.2016.10.017_bib27","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood.V124.21.4539.4539","article-title":"Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323","volume":"124","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2016.10.017_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates BCR-ABL signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2016.10.017_bib29","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.beha.2016.10.017_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines trans-formed by BCR\/ABL","volume":"183","author":"Carlesso","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"13","key":"10.1016\/j.beha.2016.10.017_bib31","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Warsch","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2016.10.017_bib32","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.10.017_bib33","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.102525","article-title":"Imatinib and ruxolitinib association: first experience in two patients","volume":"99","author":"Iurlo","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.017_bib34","first-page":"2832","article-title":"Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib","volume":"120","author":"Knoche","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.beha.2016.10.017_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2016.10.017_bib36","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.10.017_bib37","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2016.10.017_bib38","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin cancer Res"},{"key":"10.1016\/j.beha.2016.10.017_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1349-7006.1992.tb00109.x","article-title":"A\u00a0novel tetrapeptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells","volume":"83","author":"Yoshida","year":"1992","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.beha.2016.10.017_bib40","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2016.10.017_bib41","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1182\/blood.V112.11.4263.4263","article-title":"A\u00a0phase II study of oral panobinostat (LBH589) in accelerated phase (AP) or blast crisis (BC) chronic myeloid leukemia (CML) patients resistant to \u22652 BCR-ABL tyrosine kinase inhibitors","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib42","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood.V112.11.4254.4254","article-title":"A\u00a0phase II study of oral panobinostat (LBH589) for chronic phase chronic myeloid leukemia (CML) with resistance to \u22652 BCR-ABL tyrosine kinase inhibitors","volume":"112","author":"Zaritskey","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib43","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.10.017_bib44","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1038\/bcj.2014.60","article-title":"A\u00a0phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2016.10.017_bib45","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/bcj.2015.30","article-title":"Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing","volume":"5","author":"Pietarinen","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2016.10.017_bib46","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A\u00a0non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.10.017_bib47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2009.300","article-title":"ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells","volume":"24","author":"Wu","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2016.10.017_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin tar-gets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.beha.2016.10.017_bib49","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.017_bib50","series-title":"Dual targeting of BCR-ABL with ABL001: a novel potent allosteric ABL kinase inhibitor in combination with nilotinib suppresses the emergence of disease resistance in models of CML","author":"Sellers","year":"2015"},{"issue":"9","key":"10.1016\/j.beha.2016.10.017_bib51","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl\u2013positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2016.10.017_bib52","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In\u00a0vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.beha.2009.10.005","article-title":"Interferon in chronic myeloid leukaemia : past and future","volume":"22","author":"Guilhot","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2016.10.017_bib54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized, multicenter, comparative study of peginterferon alfa-2a(40KD) versus interferon alfa -2a (Roferon\u00ae-A) in patients with treatment-na\u00efve, chronic-phase chronic myelogenous leukemia","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.10.017_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study","volume":"18","author":"Michallet","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.017_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in\u00a0vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.017_bib57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.beha.2016.10.017_bib58","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2010-12-325373","article-title":"Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor","volume":"118","author":"Bhattacharya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib59","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib an pegylated human recombinant interferon-\u03b12b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib60","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-\u03b1: 5 year outcome","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.017_bib61","first-page":"3512a","article-title":"PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase Chronic Myelo\u00efd Leukemia","volume":"98","author":"O'Brien","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib62","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.017_bib63","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-\u03b1-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.017_bib64","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood.V124.21.1793.1793","volume":"124","author":"Guilhot","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib65","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg versus 400 mg versus. 400 mg + IFN in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.017_bib66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.017_bib67","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2016.10.017_bib68","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cncr.25438","volume":"117","author":"Cortes","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.017_bib69","first-page":"e37","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicenter, non randomized, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.10.017_bib70","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.017_bib71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood.V126.23.134.134","article-title":"Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC)","volume":"126","author":"Roy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib72","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.28427","article-title":"Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha","volume":"134","author":"El Eit","year":"2013","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2016.10.017_bib73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190801927510","article-title":"Immunotherapeutic approaches in chronic myelogenous Leukemia","volume":"49","author":"Guilhot","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.beha.2016.10.017_bib74","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to BCR-ABL oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib75","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2000.02090.x","article-title":"b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukemia","volume":"109","author":"Norbury","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.017_bib76","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0264-410X(94)80052-2","article-title":"Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma","volume":"12","author":"Livingston","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.beha.2016.10.017_bib77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","article-title":"A\u00a0multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia","volume":"103","author":"Cathcart","year":"2003","journal-title":"Blood"},{"issue":"9460","key":"10.1016\/j.beha.2016.10.017_bib78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.10.017_bib79","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.017_bib80","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib81","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.017_bib82","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A\u00a0TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL1 leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2016.10.017_bib83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A\u00a0Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.beha.2016.10.017_bib84","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.18632\/oncotarget.1925","article-title":"The BCL2 inhibitor ABT-199 significantly enhances imatinib induced cell death in chronic myeloid leukemia progenitors","volume":"5","author":"Ko","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2016.10.017_bib85","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.leukres.2014.05.007","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives","volume":"38","author":"Heiblig","year":"2014","journal-title":"Leu Res"},{"key":"10.1016\/j.beha.2016.10.017_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","author":"Prost","year":"2015","journal-title":"Nature"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T22:58:29Z","timestamp":1718837909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1521692616300706"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.017","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond tyrosine kinase inhibitors: Combinations and other agents","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}